Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy

The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after (131)I-tositumomab radioimmunotherapy for potential use in treatment planning. METHODS: Tumor-absorbed dose measures were estimated for 130 tumors in 39 rela...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Nucl Med
मुख्य लेखकों: Dewaraja, Yuni K., Schipper, Matthew J., Shen, Jincheng, Smith, Lauren B., Murgic, Jure, Savas, Hatice, Youssef, Ehab, Regan, Denise, Wilderman, Scott J., Roberson, Peter L., Kaminski, Mark S., Avram, Anca M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237694/
https://ncbi.nlm.nih.gov/pubmed/24842891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.113.136044
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन